Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Riccardo Ragionieri"'
Autor:
Michele Cavo, Simona Soverini, Roberto Marasca, Carmela Anna Maria Tomaselli, Antonio De Vivo, Miriam Fogli, Monica Crugnola, Donato Mannina, Elena Trabacchi, Sergio Siragusa, Maurizio Musso, Fabio Stagno, Isabella Capodanno, Michele Baccarani, Patrizia Tosi, Stefana Impera, Giovanni Martinelli, Alessandro Zironi, Riccardo Ragionieri, Marzia Salvucci, Fausto Castagnetti, Francesco Cavazzini, Gianantonio Rosti, Francesco Fabbiano, Paolo Vigneri, Giuseppe Mineo, Francesco Di Raimondo, Michele Rizzo, Caterina Musolino, Antonio Spitaleri, Gabriele Gugliotta, Agostino Antolino
Publikováno v:
American Journal of Hematology. 92:82-87
Chronic myeloid leukemia (CML) treatment is based on company-sponsored and academic trials testing different tyrosine kinase inhibitors (TKIs) as first-line therapy. These studies included patients selected according to many inclusion-exclusion crite
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3863d72a5f0e0c86b8fe1e71330778e8
https://doi.org/10.1002/ajh.24591
https://doi.org/10.1002/ajh.24591
Autor:
Fausto Castagnetti, Gabriele Gugliotta, Elena Trabacchi, Michele Rizzo, Carmela Anna Maria Tomaselli, Gianantonio Rosti, Monica Crugnola, Agostino Antolino, Caterina Musolino, Sergio Siragusa, Donato Mannina, Michele Baccarani, Fabio Stagno, Simona Soverini, Patrizia Tosi, F. Cavazzini, Riccardo Ragionieri, Isabella Capodanno, Paolo Vigneri, Giovanni Martinelli, Maurizio Musso, Giuseppe Mineo, Francesco Di Raimondo, Alessandro Zironi, Michele Cavo, Antonio Spitaleri, Antonio De Vivo, Miriam Fogli, Roberto Marasca, Stefana Impera, Marzia Salvucci, Francesco Fabbiano
Background. Chronic myeloid leukemia (CML) treatment is based on company-sponsored and academic trials testing different tyrosine kinase inhibitors (TKIs) as first-line therapies. However these clinical trials included patients selected according to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce922f39de94469915d4dc6eb788193f
http://hdl.handle.net/11392/2372167
http://hdl.handle.net/11392/2372167
Autor:
Lucia Canafoglia, Micaela Bergamaschi, Cristina Santoro, Francesco Spina, Bruno Martino, Gabriele Gugliotta, Emma Cacciola, Daniele Cattaneo, Giovanni Garozzo, Alessandra Perra, Katia Codeluppi, Annalisa Luraschi, Raffaele Palmieri, G Ferrara, Viviana Appolloni, Alfredo Dragani, Erminia Rinaldi, Anna Candoni, Mauro Di Ianni, Umberto Santoro, Rossella R. Cacciola, Potito Rosario Scalzulli, Crescenza Pasciolla, Oreste Villani, Maria Langella, Giovanni Caocci, Francesco Lanza, Anna Da Col, Maria Luigia Randi, Elena Masselli, Elisa Rumi, Alessandro M. Vannucchi, Paola Ranalli, Giuseppe Tagariello, Nicola Orofino, Angela Rago, Daniela Lambertenghi, Anna Marina Liberati, Alessia Tieghi, Lorenzo Rizzo, Aniello Casoria, Rupoli Serena, Alessandra Iurlo, Manlio Ricciotti, Luigi Gugliotta, Riccardo Ragionieri, Monica Crugnola, Nilla Maschio, Nicola Vianelli, Emilio Usala, Giorgio La Nasa, Elisabetta Cosi
Publikováno v:
Blood. 128:5472-5472
Background: the Registro Italiano Trombocitemie (RIT) was activated mainly to evaluate the diagnosis and therapy appropriateness in the thrombocythemic patients with Ph-negative myeloproliferative neoplasm (MPN) observed in the adhering centers. Obje
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8444a7ccf8b9541da9f2069b7d7d5d69
https://doi.org/10.1182/blood.v128.22.5472.5472
https://doi.org/10.1182/blood.v128.22.5472.5472